COVID-19: Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries

Must Read

How To Block Your Bank Account And SIM Card In Case Of Emergency

Losing your phone and wallet or having them stolen can be very frustrating. However, in case that happens to...

Ibadan-Born Billionaire, Harry Akande is dead

Harry Ayoade Akande has died at the age of 77. He died on Saturday morning of an undisclosed ‘brief...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...
- Advertisement -

As of today, Sanofi has committed to donating 100 million doses of hydroxychloroquine to 50 countries around the world and has begun to progressively deliver the medicine to authorities that have requested it.

Hydroxychloroquine donation

In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for currently approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations.

Since the beginning of the COVID-19 crisis, Sanofi has received a growing number of requests from local governments around the world. The company is regularly evaluating its increasing supply capacity and re-assessing how best to help those countries in the most ethical way. Sanofi’s priority is to ensure supply continuity for patients treated under the currently approved indications of the medicine, notably including lupus and rheumatoid arthritis while working hard to supply governments wishing to increase stocks in the hope that it may be an effective treatment of COVID-19.

- Advertisement -

Sanofi will continue to donate the medicine to governments and hospital institutions if ongoing clinical studies demonstrate its efficacy and safety in COVID-19 patients.

Production capacity ramp-up

Sanofi has already doubled its incremental production capacity (on top of the usual production for current indications) across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

Call for greater international cooperation

- Advertisement -

Sanofi is calling for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries”, says Paul Hudson, Chief Executive Officer at Sanofi. “This virus does not care about the concept of borders, so we shouldn’t either. It is critical that international authorities, local governments, manufacturers, and all the other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients.

The company is already actively working with different stakeholders at local and international levels, and is ready to play its part in contributing to a more coordinated global initiative.

Read Also:  Unitar's Response To Covid-19 Pandemic

Ensure patient safety

- Advertisement -

At this point, the interpretations of the available preliminary data on hydroxychloroquine in the management of COVID-19 differ widely. In this context, patient safety must always be the guiding principle.

Hydroxychloroquine has several serious known side effects and should be used with caution.  Not everyone can take this medicine.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients. It is one of several medicines being investigated by the World Health Organization (WHO) in its international clinical trial seeking a treatment solution for COVID-19. Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centers.

Read Also:  COVID-19: Work from Home, Sanwo-Olu Directs Civil Servants from Level 1 to 12

While hydroxychloroquine is generating a lot of hope for patients around the world, it should be remembered that there are no results from ongoing studies, and the results may be positive or negative.

Sanofi’s efforts in the fight against COVID-19

Sanofi remains at the forefront of initiatives to fight the coronavirus, while also carrying on the daily business of making and delivering important medicines for patients. The company is also exploring alternative treatment options such as Kevzara® (sarilumab) for severe COVID-19 patients, and leveraging its expertise to develop a new vaccine. Both measures could have an immediate and a lasting impact. Dealing with a pandemic as daunting as COVID-19 requires collaboration to create as many paths forward as possible, and Sanofi is helping lead the way, playing its part.

- Advertisement -
COVID-19:  Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries - Brand SpurCOVID-19:  Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

COVID-19:  Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries - Brand SpurCOVID-19:  Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries - Brand Spur

Latest News

Ibadan-Born Billionaire, Harry Akande is dead

Harry Ayoade Akande has died at the age of 77. He died on Saturday morning of an undisclosed ‘brief...

NSE ASI Revs by 0.72% on Insurance, Oil/Gas Stocks

In line with our expectations, investors in the equities market remained bullish, especially on insurance and oil & gas stocks. Hence, the All-Share Index...

Red Hat Releases 2021 Global Tech Outlook Survey

For the fifth consecutive year, Red Hat has released its annual Global Tech Outlook. This survey of IT leaders covers the top IT challenges and funding...

Net Inflow Worth N281.10 billion via OMO Create Liquidity Ease.

In the just concluded week, CBN refinanced only N60 billion of the N341.10 billion treasury bills which matured via the Open Market Operation (OMO)....

Naira Gains against the USD at BDC, Black Markets amid New Forex Policy…

In the just concluded week, Naira gained against the USD at the Bureau De Change (BDC) and parallel (“black”) markets by 4.12% and 4.04%...
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -COVID-19:  Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries - Brand SpurCOVID-19:  Sanofi to Donate 100 Million Doses Of hydroxychloroquine Across 50 Countries - Brand Spur